Symbols / MBRX Stock $2.41 -2.43% Moleculin Biotech, Inc.

Healthcare • Biotechnology • United States • NCM
MBRX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Walter V. Klemp
Exch · Country NCM · United States
Market Cap 12.86M
Enterprise Value 2.87M
Income -42.37M
Sales —
FCF (ttm) -13.15M
Book/sh 4.69
Cash/sh 1.93
Employees 17
Insider 10d —
IPO Jun 02, 2016
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.02
PEG —
P/S —
P/B 0.51
P/C —
EV/EBITDA -0.11
EV/Sales —
Quick Ratio 1.30
Current Ratio 1.38
Debt/Eq 2.15
LT Debt/Eq —
EPS (ttm) -16.16
EPS next Y -110.50
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-14
Earnings (prior) 2026-05-14
ROA -76.15%
ROE -5.32%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 5.34M
Shs Float 5.29M
Insider Own 0.83%
Instit Own 4.40%
Short Float 15.67%
Short Ratio 3.41
Short Interest 828.96K
52W High 24.00
vs 52W High -89.96%
52W Low 1.79
vs 52W Low 34.64%
Beta 1.77
Impl. Vol. —
Rel Volume 0.97
Avg Volume 175.17K
Volume 169.36K
Target (mean) $21.00
Tgt Median $22.00
Tgt Low $10.00
Tgt High $31.00
# Analysts 3
Recom None
Prev Close $2.47
Price $2.41
Change -2.43%
About

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$21.00
Mean price target
2. Current target
$2.41
Latest analyst target
3. DCF / Fair value
$-44.37
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.41
Low
$10.00
High
$31.00
Mean
$21.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-24 reit HC Wainwright & Co. Buy → Buy $22
2025-12-11 main HC Wainwright & Co. Buy → Buy $22
2025-09-10 reit HC Wainwright & Co. Buy → Buy $4
2025-08-27 reit HC Wainwright & Co. Buy → Buy $4
2025-06-18 reit HC Wainwright & Co. Buy → Buy $4
2025-03-25 up Maxim Group Hold → Buy $4
2025-03-25 reit HC Wainwright & Co. Buy → Buy $8
2025-03-24 reit HC Wainwright & Co. Buy → Buy $8
2025-03-03 main HC Wainwright & Co. Buy → Buy $8
2024-11-12 main Maxim Group Buy → Buy $8
2024-04-12 main Roth MKM Buy → Buy $40
2024-03-26 main Maxim Group Buy → Buy $20
2023-12-14 init HC Wainwright & Co. — → Buy $3
2023-04-18 main Roth MKM — → Buy $16
2023-03-24 reit Oppenheimer — → Outperform $5
News
RSS: Latest MBRX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-11-04 PICKER DONALD H Officer — 8,750 — —
2025-11-04 KLEMP WALTER V. Chief Executive Officer — 28,750 — —
2025-11-04 FOSTER JONATHAN P. Chief Financial Officer — 20,625 — —
2025-06-23 KLEMP WALTER V. Chief Executive Officer — 675,675 $0.37 $250,000
2025-06-23 FOSTER JONATHAN P. Chief Financial Officer — 270,270 $0.37 $100,000
2025-06-20 PICKER DONALD H Officer — 2,844 — —
2025-06-20 KLEMP WALTER V. Chief Executive Officer — 12,740 — —
2025-06-20 FOSTER JONATHAN P. Chief Financial Officer — 7,039 — —
2025-06-16 KLEMP WALTER V. Chief Executive Officer — 1,667 — —
2025-06-16 FOSTER JONATHAN P. Chief Financial Officer — 833 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
25.10
-5.77%
26.64
-10.09%
29.63
-3.29%
30.64
Research And Development
15.89
-10.37%
17.73
-9.02%
19.49
+2.74%
18.97
Selling General And Administration
9.12
+3.82%
8.79
-12.29%
10.02
-13.21%
11.54
General And Administrative Expense
9.12
+3.82%
8.79
-12.29%
10.02
-13.21%
11.54
Other Gand A
9.12
+3.82%
8.79
-12.29%
10.02
-13.21%
11.54
Total Expenses
25.10
-5.77%
26.64
-10.09%
29.63
-3.29%
30.64
Operating Income
-25.10
+5.77%
-26.64
+10.09%
-29.63
+3.29%
-30.64
Total Operating Income As Reported
-25.10
+5.77%
-26.64
+10.09%
-29.63
+3.29%
-30.64
EBITDA
-25.01
+5.66%
-26.52
+10.13%
-29.50
+3.30%
-30.51
Normalized EBITDA
-16.47
+37.88%
-26.52
+5.13%
-27.95
+12.23%
-31.84
Reconciled Depreciation
0.09
-28.57%
0.13
-0.79%
0.13
-2.31%
0.13
EBIT
-25.10
+5.77%
-26.64
+10.09%
-29.63
+3.29%
-30.64
Total Unusual Items
-8.54
0.00
+100.00%
-1.55
-216.40%
1.33
Total Unusual Items Excluding Goodwill
-8.54
0.00
+100.00%
-1.55
-216.40%
1.33
Special Income Charges
-0.61
0.00
—
—
Other Special Charges
0.61
—
—
—
Net Income
-33.56
-28.84%
-26.05
+12.50%
-29.77
-2.56%
-29.02
Pretax Income
-33.56
-28.84%
-26.05
+12.50%
-29.77
-2.56%
-29.02
Net Non Operating Interest Income Expense
0.10
-80.91%
0.55
-59.80%
1.37
+470.00%
0.24
Net Interest Income
0.10
-80.91%
0.55
-59.80%
1.37
+470.00%
0.24
Interest Income Non Operating
0.10
-80.91%
0.55
-59.80%
1.37
+470.00%
0.24
Interest Income
0.10
-80.91%
0.55
-59.80%
1.37
+470.00%
0.24
Other Income Expense
-8.56
-20011.63%
0.04
+102.86%
-1.51
-209.53%
1.38
Other Non Operating Income Expenses
-0.02
-146.51%
0.04
-10.42%
0.05
+20.00%
0.04
Gain On Sale Of Security
-7.93
-285.02%
4.29
+375.74%
-1.55
-216.40%
1.33
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-33.56
-28.84%
-26.05
+12.50%
-29.77
-2.56%
-29.02
Net Income From Continuing Operation Net Minority Interest
-33.56
-28.84%
-26.05
+12.50%
-29.77
-2.56%
-29.02
Net Income From Continuing And Discontinued Operation
-33.56
-28.84%
-26.05
+12.50%
-29.77
-2.56%
-29.02
Net Income Continuous Operations
-33.56
-28.84%
-26.05
+12.50%
-29.77
-2.56%
-29.02
Normalized Income
-25.02
+3.95%
-26.05
+7.68%
-28.21
+7.07%
-30.36
Net Income Common Stockholders
-33.66
-29.24%
-26.05
+12.50%
-29.77
-2.56%
-29.02
Otherunder Preferred Stock Dividend
0.10
0.00
—
—
Diluted EPS
-28.42
+84.97%
-189.14
+49.80%
-376.75
+0.53%
-378.75
Basic EPS
-28.42
+84.97%
-189.14
+49.80%
-376.75
+0.53%
-378.75
Basic Average Shares
1.18
+760.13%
0.14
+74.28%
0.08
+3.60%
0.08
Diluted Average Shares
1.18
+760.13%
0.14
+74.28%
0.08
+3.60%
0.08
Diluted NI Availto Com Stockholders
-33.66
-29.24%
-26.05
+12.50%
-29.77
-2.56%
-29.02
Depreciation Amortization Depletion Income Statement
0.09
-28.57%
0.13
-0.79%
0.13
-2.31%
0.13
Depreciation And Amortization In Income Statement
0.09
-28.57%
0.13
-0.79%
0.13
-2.31%
0.13
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
22.13
+30.73%
16.93
-55.71%
38.22
-33.45%
57.42
Current Assets
9.69
+86.48%
5.19
-80.23%
26.27
-42.38%
45.60
Cash Cash Equivalents And Short Term Investments
8.88
+107.53%
4.28
-81.83%
23.55
-45.42%
43.15
Cash And Cash Equivalents
8.88
+107.53%
4.28
-81.83%
23.55
-45.42%
43.15
Receivables
0.01
-65.00%
0.02
-79.80%
0.10
+350.00%
0.02
Other Receivables
0.01
-65.00%
0.02
-78.95%
0.10
+4650.00%
0.00
Prepaid Assets
0.80
-10.60%
0.90
-65.85%
2.62
+8.03%
2.43
Total Non Current Assets
12.44
+6.04%
11.73
-1.78%
11.94
+1.00%
11.83
Net PPE
0.39
-32.76%
0.58
-26.76%
0.80
+17.40%
0.68
Gross PPE
0.39
-32.76%
0.58
-65.54%
1.69
+16.93%
1.45
Accumulated Depreciation
—
-1.02
-14.06%
-0.90
-16.51%
-0.77
Machinery Furniture Equipment
0.08
-50.94%
0.16
-86.39%
1.17
+11.88%
1.04
Other Properties
0.31
-25.94%
0.42
-19.08%
0.52
+30.02%
0.40
Goodwill And Other Intangible Assets
11.15
+0.00%
11.15
+0.00%
11.15
+0.00%
11.15
Other Intangible Assets
11.15
+0.00%
11.15
+0.00%
11.15
—
Non Current Prepaid Assets
0.90
0.00
—
—
Other Non Current Assets
0.90
—
—
—
Total Liabilities Net Minority Interest
7.12
+24.54%
5.72
-52.92%
12.14
+132.15%
5.23
Current Liabilities
6.85
+27.90%
5.36
-21.36%
6.82
+41.42%
4.82
Payables And Accrued Expenses
6.72
+28.21%
5.24
-21.98%
6.71
+42.78%
4.70
Payables
3.51
+72.81%
2.03
-20.64%
2.56
+17.29%
2.18
Accounts Payable
3.51
+72.81%
2.03
-18.73%
2.50
+19.24%
2.10
Current Accrued Expenses
3.21
+0.00%
3.21
-22.80%
4.16
+64.83%
2.52
Current Debt And Capital Lease Obligation
0.14
+14.17%
0.12
+20.00%
0.10
-13.79%
0.12
Current Capital Lease Obligation
0.14
+14.17%
0.12
+20.00%
0.10
-13.79%
0.12
Total Non Current Liabilities Net Minority Interest
0.27
-25.70%
0.36
-93.28%
5.33
+1193.45%
0.41
Long Term Debt And Capital Lease Obligation
0.22
-37.99%
0.36
-24.47%
0.47
+41.49%
0.34
Long Term Capital Lease Obligation
0.22
-37.99%
0.36
-24.47%
0.47
+41.49%
0.34
Stockholders Equity
15.01
+33.89%
11.21
-57.01%
26.07
-50.04%
52.19
Common Stock Equity
15.01
+33.89%
11.21
-57.01%
26.07
-50.04%
52.19
Capital Stock
0.00
0.00
-100.00%
0.03
+13.79%
0.03
Common Stock
0.00
0.00
-100.00%
0.03
+13.79%
0.03
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
3.20
+2267.08%
0.14
+51.69%
0.09
+16.71%
0.08
Ordinary Shares Number
3.20
+2267.08%
0.14
+51.69%
0.09
+16.71%
0.08
Additional Paid In Capital
221.00
+20.31%
183.69
+16.52%
157.65
+2.38%
153.99
Retained Earnings
-206.00
-19.46%
-172.44
-31.03%
-131.60
-29.23%
-101.83
Gains Losses Not Affecting Retained Earnings
0.01
+124.39%
-0.04
-355.56%
-0.01
-175.00%
0.01
Other Equity Adjustments
0.01
+124.39%
-0.04
-355.56%
-0.01
-175.00%
0.01
Total Equity Gross Minority Interest
15.01
+33.89%
11.21
-57.01%
26.07
-50.04%
52.19
Total Capitalization
15.01
+33.89%
11.21
-57.01%
26.07
-50.04%
52.19
Working Capital
2.83
+1816.36%
-0.17
-100.85%
19.46
-52.28%
40.78
Invested Capital
15.01
+33.89%
11.21
-57.01%
26.07
-50.04%
52.19
Total Debt
0.36
-24.90%
0.48
-16.72%
0.57
+27.27%
0.45
Capital Lease Obligations
0.36
-24.90%
0.48
-16.72%
0.57
+27.27%
0.45
Net Tangible Assets
3.86
+6330.00%
0.06
-99.60%
14.93
-63.64%
41.04
Tangible Book Value
3.86
+6330.00%
0.06
-99.60%
14.93
-63.64%
41.04
Derivative Product Liabilities
0.04
0.00
-100.00%
4.86
+6205.19%
0.08
Duefrom Related Parties Current
—
0.00
+0.00%
0.00
-80.00%
0.02
Dueto Related Parties Current
—
0.13
+116.67%
0.06
-30.23%
0.09
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-22.73
+4.72%
-23.86
-1.15%
-23.59
+14.65%
-27.64
Cash Flow From Continuing Operating Activities
-22.73
+4.72%
-23.86
-1.15%
-23.59
+14.65%
-27.64
Net Income From Continuing Operations
-33.56
-28.84%
-26.05
+12.50%
-29.77
-2.56%
-29.02
Depreciation Amortization Depletion
0.09
-28.57%
0.13
-0.79%
0.13
-2.31%
0.13
Depreciation And Amortization
0.09
-28.57%
0.13
-0.79%
0.13
-2.31%
0.13
Other Non Cash Items
-0.03
-125.24%
0.10
-88.44%
0.89
+868.48%
0.09
Stock Based Compensation
1.66
-3.59%
1.73
-13.00%
1.98
-12.79%
2.27
Operating Gains Losses
8.54
+299.35%
-4.29
-375.74%
1.55
+216.40%
-1.33
Gain Loss On Investment Securities
8.54
+299.35%
-4.29
-375.74%
1.55
+216.40%
-1.33
Gain Loss On Sale Of PPE
—
—
—
—
Change In Working Capital
0.56
+140.26%
0.23
-85.76%
1.62
+624.11%
0.22
Change In Prepaid Assets
-0.79
-143.83%
1.81
+764.34%
-0.27
+68.26%
-0.86
Change In Payables And Accrued Expense
1.35
+185.47%
-1.58
-183.21%
1.89
+75.21%
1.08
Change In Accrued Expense
0.02
+101.53%
-1.11
-174.31%
1.49
+326.00%
0.35
Change In Payable
1.33
+384.19%
-0.47
-216.13%
0.40
-44.87%
0.73
Change In Account Payable
1.33
+384.19%
-0.47
-216.13%
0.40
-44.87%
0.73
Investing Cash Flow
0.00
+100.00%
-0.01
+89.52%
-0.12
-85.07%
-0.07
Cash Flow From Continuing Investing Activities
0.00
+100.00%
-0.01
+89.52%
-0.12
-85.07%
-0.07
Net PPE Purchase And Sale
0.00
+100.00%
-0.01
+89.52%
-0.12
-85.07%
-0.07
Purchase Of PPE
0.00
+100.00%
-0.01
+89.52%
-0.12
-85.07%
-0.07
Sale Of PPE
—
—
—
—
Capital Expenditure
—
-0.01
+89.52%
-0.12
-85.07%
-0.07
Financing Cash Flow
27.28
+488.65%
4.63
+11.93%
4.14
+18104.35%
-0.02
Cash Flow From Continuing Financing Activities
27.28
+488.65%
4.63
+11.93%
4.14
+18104.35%
-0.02
Net Common Stock Issuance
25.77
+452.90%
4.66
+11.86%
4.17
0.00
Proceeds From Stock Option Exercised
1.53
+152600.00%
0.00
0.00
0.00
Net Other Financing Charges
-0.01
+69.23%
-0.03
-4.00%
-0.03
-8.70%
-0.02
Changes In Cash
4.55
+123.64%
-19.24
+1.71%
-19.57
+29.41%
-27.73
Effect Of Exchange Rate Changes
0.05
+259.38%
-0.03
-52.38%
-0.02
+27.59%
-0.03
Beginning Cash Position
4.28
-81.83%
23.55
-45.42%
43.15
-39.15%
70.90
End Cash Position
8.88
+107.53%
4.28
-81.83%
23.55
-45.42%
43.15
Free Cash Flow
-22.73
+4.77%
-23.88
-0.67%
-23.71
+14.40%
-27.71
Interest Paid Supplemental Data
—
—
—
—
Income Tax Paid Supplemental Data
—
—
—
—
Common Stock Issuance
25.77
+452.90%
4.66
+11.86%
4.17
0.00
Issuance Of Capital Stock
25.77
+452.90%
4.66
+11.86%
4.17
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category